1 / 17

Enhancing Collaboration in Health Technology Assessment: EUnetHTA Overview

Learn about EUnetHTA's objectives, joint production assessments, patient input importance, and the future of pharma assessments. Enhance collaboration, align processes, and increase efficiency in HTA to drive sustainable healthcare models.

lboykin
Download Presentation

Enhancing Collaboration in Health Technology Assessment: EUnetHTA Overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CURRENT EU COOPERATION ON HEALTH TECHNOLOGY ASSESSORS: EUnetHTA Friday 11 May, 2018 – 9th ERCD, Vienna Anne Willemsen, MSc EUnetHTA WP4 Co-Lead pharmaceuticals Dutch National Healthcare Insitute – Zorginstituut Nederland (ZIN)

  2. European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu Key objectives of EUnetHTA JA3

  3. Joint Action 3 Objectives Sustainable model for joint HTA work Increase use, quality and efficiency of HTA Increase collaboration Increase production Increase usage Sharing knowledge Alignment of processes Implementation

  4. DG Santé and CHAFEA Organisational and governance structure EUnetHTA Assembly Executive Board Overall coordination – Dutch Health Care Institute

  5. European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu Joint Production of Relative Effectiveness Assessments: towards implementation Flow of activities

  6. Joint Assessments JA2 - Pharma Status REA Other technologies

  7. Status Joint Assessments JA3 - Pharma Status REA Other technologies

  8. Scoping phase European network for Health Technology Assessment | JA2 2012-2015 | www.eunethta.eu

  9. Assessment phase European network for Health Technology Assessment | JA2 2012-2015 | www.eunethta.eu

  10. Patient input highly valued!!  Input during scopingphase

  11. Activity flow around patient engagement EUnetHTA wide task group • Outcomes discussed with patients organisations • Evaluate impact patient engagement on report • Evaluate diversity patients involved Based on HTAi questionnaire template • Language barrier?  translate to national language • Develop interview guide  ensure consistency Visibility patient input in reports • Start: • Discussions on publishing interview summaries • Outcomes informed by patients?

  12. Future of Joint Assessments on pharma?

  13. Evaluation and Revision Feedback authoring team and other stakeholders (e.g. industry, patient organisations) Simplify the production process​ • Focus on scope: Patient, Intervention, Comparator, Outcome • Seek input from all EUnetHTA partners    ​ Patient and clinician engagement Implementation

  14. Further enhance implementation? • EUnetHTA is not a legal entity • Developing EUnetHTA ‘guidance’ on • Confidentiality • Conflict of Interest • Compensation • Increase production assessments • Allow for growing experience national level • Legal/organisational barriers? • E.g. Language a barrier for uptake?

  15. Thank you!

More Related